These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35602255)

  • 1. ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation.
    Di Fusco SA; Gronda E; Mocini E; Lucà F; Bisceglia I; De Luca L; Caldarola P; Cipriani M; Corda M; De Nardo A; Francese GM; Napoletano C; Navazio A; Riccio C; Roncon L; Tizzani E; Nardi F; Urbinati S; Valente S; Gulizia MM; Gabrielli D; Oliva F; Imperoli G; Colivicchi F
    Eur Heart J Suppl; 2022 May; 24(Suppl C):C272-C277. PubMed ID: 35602255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure].
    Di Fusco SA; Spinelli A; Aquilani S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Jan; 24(1):66-74. PubMed ID: 36573513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA; Pinner NA; Lisenby KM; Osmonson A
    Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives.
    Jensen J; Omar M; Kistorp C; Gustafsson F; Køber L; Møller JE; Schou M
    Basic Clin Pharmacol Toxicol; 2022 Jul; 131(1):5-17. PubMed ID: 35510595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
    Genuardi MV; Mather PJ
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211002678. PubMed ID: 33779401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases].
    Lu H; Hullin R; Yerly P; Meyer P; Kosinski C; Daux A
    Rev Med Suisse; 2021 May; 17(740):1034-1038. PubMed ID: 34042339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
    Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy.
    Naito R; Kasai T
    World J Cardiol; 2021 Sep; 13(9):464-471. PubMed ID: 34621491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
    Blair HA
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):701-710. PubMed ID: 34651263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.
    Abdelhamid M; Kandil H; Hassanin M; Shaheen S; Sobhy M; ElEtreby A; Hasan-Ali H; Mahfouz H; Nasr G; Shawky I; Emil S; ElSetiha M; Hasssan M; Sadek Y; Karim MA; Asham A; Ghaleb M; Samir A; Shokry K
    ESC Heart Fail; 2022 Apr; 9(2):800-811. PubMed ID: 35118822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.
    Vardeny O; Vaduganathan M
    JACC Heart Fail; 2019 Feb; 7(2):169-172. PubMed ID: 30704605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SGLT2 inhibitors - a new pillar for the treatment of heart failure].
    Tavačová D; Václavík J
    Vnitr Lek; 2021; 67(8):475-478. PubMed ID: 35459367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.